Free
Pain Medicine  |   May 2016
Persistent Catechol-O-methyltransferase–dependent Pain Is Initiated by Peripheral β-Adrenergic Receptors
Author Notes
  • From the Dental Research Department, Center for Pain Research and Innovation, University of North Carolina, Chapel Hill, North Carolina. Current affiliation: Center for Translational Pain Medicine, Department of Anesthesiology, Duke University School of Medicine, Durham, North Carolina (A.G.N.).
  • Corresponding article on page 994.
    Corresponding article on page 994.×
  • Supplemental Digital Content is available for this article. Direct URL citations appear in the printed text and are available in both the HTML and PDF versions of this article. Links to the digital files are provided in the HTML text of this article on the Journal’s Web site (www.anesthesiology.org).
    Supplemental Digital Content is available for this article. Direct URL citations appear in the printed text and are available in both the HTML and PDF versions of this article. Links to the digital files are provided in the HTML text of this article on the Journal’s Web site (www.anesthesiology.org).×
  • Submitted for publication August 31, 2015. Accepted for publication February 9, 2016.
    Submitted for publication August 31, 2015. Accepted for publication February 9, 2016.×
  • Address correspondence to Dr. Nackley: Center for Translational Pain Medicine, Department of Anesthesiology, Duke University School of Medicine, 905 South LaSalle Street, No. 1010, Durham, North Carolina 27710. andrea.nackley@duke.edu. Information on purchasing reprints may be found at www.anesthesiology.org or on the masthead page at the beginning of this issue. Anesthesiology’s articles are made freely accessible to all readers, for personal use only, 6 months from the cover date of the issue.
Article Information
Pain Medicine / Basic Science / Pain Medicine
Pain Medicine   |   May 2016
Persistent Catechol-O-methyltransferase–dependent Pain Is Initiated by Peripheral β-Adrenergic Receptors
Anesthesiology 5 2016, Vol.124, 1122-1135. doi:10.1097/ALN.0000000000001070
Anesthesiology 5 2016, Vol.124, 1122-1135. doi:10.1097/ALN.0000000000001070
Abstract

Background: Patients with chronic pain disorders exhibit increased levels of catecholamines alongside diminished activity of catechol-O-methyltransferase (COMT), an enzyme that metabolizes catecholamines. The authors found that acute pharmacologic inhibition of COMT in rodents produces hypersensitivity to mechanical and thermal stimuli via β-adrenergic receptor (βAR) activation. The contribution of distinct βAR populations to the development of persistent pain linked to abnormalities in catecholamine signaling requires further investigation.

Methods: Here, the authors sought to determine the contribution of peripheral, spinal, and supraspinal βARs to persistent COMT-dependent pain. They implanted osmotic pumps to deliver the COMT inhibitor OR486 (Tocris, USA) for 2 weeks. Behavioral responses to mechanical and thermal stimuli were evaluated before and every other day after pump implantation. The site of action was evaluated in adrenalectomized rats receiving sustained OR486 or in intact rats receiving sustained βAR antagonists peripherally, spinally, or supraspinally alongside OR486.

Results: The authors found that male (N = 6) and female (N = 6) rats receiving sustained OR486 exhibited decreased paw withdrawal thresholds (control 5.74 ± 0.24 vs. OR486 1.54 ± 0.08, mean ± SEM) and increased paw withdrawal frequency to mechanical stimuli (control 4.80 ± 0.22 vs. OR486 8.10 ± 0.13) and decreased paw withdrawal latency to thermal heat (control 9.69 ± 0.23 vs. OR486 5.91 ± 0.11). In contrast, adrenalectomized rats (N = 12) failed to develop OR486-induced hypersensitivity. Furthermore, peripheral (N = 9), but not spinal (N = 4) or supraspinal (N = 4), administration of the nonselective βAR antagonist propranolol, the β2AR antagonist ICI-118,511, or the β3AR antagonist SR59230A blocked the development of OR486-induced hypersensitivity.

Conclusions: Peripheral adrenergic input is necessary for the development of persistent COMT-dependent pain, and peripherally-acting βAR antagonists may benefit chronic pain patients.

Abstract

In rats, sustained administration of a catecholamine-O-methyltransferase inhibitor produces hypersensitivity to mechanical and thermal stimuli, which is prevented by peripheral, but not spinal or supraspinal, administration of β-adrenoceptor antagonists, suggesting a peripheral site of action.

Supplemental Digital Content is available in the text.

What We Already Know about This Topic
  • Decreased catecholamine-O-methyltransferase activity is associated with increased clinical and experimental pain in humans, and inhibition of catecholamine-O-methyltransferase in animals results in hypersensitivity

  • Although β-adrenoceptors appear important to these observations, the sites of receptor activation are unknown

What This Article Tells Us That Is New
  • In rats, sustained administration of a catecholamine-O-methyltransferase inhibitor produces hypersensitivity to mechanical and thermal stimuli, which is prevented by peripheral, but not spinal or supraspinal, administration of β-adrenoceptor antagonists, suggesting a peripheral site of action

CHRONIC pain disorders, including fibromyalgia, headache, temporomandibular disorder (TMD), and vestibulodynia, constitute a significant healthcare problem, affecting more than 100 million Americans.1–7  These disorders occur more frequently in women than in men8  and are persistent in nature, characterized by pain that occurs daily and spans years. While the mechanisms underlying chronic pain are poorly understood, emerging evidence indicates a role for adrenergic pathways. Patients with chronic pain exhibit increased levels of catecholamines9–11  alongside diminished activity of catechol-O-methyltransferase (COMT),12,13  a ubiquitously expressed enzyme that metabolizes catecholamines to their inactive derivatives.14  An increase in catecholamines is similarly observed in patients with inflammatory conditions such as arthritis and complex regional pain syndrome (CRPS).15–17  Furthermore, functional variants in the COMT gene that reduce COMT activity13,18,19  are associated with increased susceptibility to fibromyalgia,20–24  TMD,25  and experimental pain25,26  as well as impaired response to treatment.27,28  It is estimated, based on the frequency of allele variation, that nearly two thirds of patients with chronic pain disorders possess the low-activity COMT variants.20 ,29
Consistent with clinical disorders, we found in our laboratory that administration of the COMT inhibitor OR486 (Tocris, USA) in rodents produces increased hypersensitivity at multiple body sites and alters cognitive–affective behaviors linked to pain (e.g., avoidance of painful heat and bright light).30–32  Pharmacologic studies further revealed that OR486-induced hypersensitivity is blocked by administration of the nonselective β-adrenergic receptor (βAR) antagonist propranolol or by combined administration of selective β2- and β3AR antagonists.30–32  These results are in line with those from clinical studies, showing that propranolol alleviates pain among fibromyalgia and TMD patients.33,34  Collectively, these studies suggest that increased catecholamine levels, resulting from reduced COMT activity, drive pain via β2- and β3ARs.
β2- and β3ARs are G-protein–coupled receptors expressed in peripheral and central regions where they could drive pain. β2ARs are located on peripheral terminals35–39  and cell bodies40–42  of primary afferent nociceptors; keratinocytes,43–45  immune cells,46–49  and adipocytes50  in the periphery; and neurons51,52  and glial cells53  in the central nervous system. β3ARs are located on primary afferent nociceptors,54  adipocytes50  and immune cells47,48  in the periphery, and noradrenergic neurons in the brain.55  Thus, we hypothesized that peripheral, spinal, and/or supraspinal β2- and β3ARs contribute to persistent COMT-dependent pain.
To test this hypothesis, we employed a clinically-relevant model of persistent COMT-dependent pain and evaluated responses to mechanical and thermal stimuli in adrenalectomized rats lacking peripheral epinephrine, and in intact rats receiving continuous delivery of βAR antagonists via intraplantar, intrathecal, or intracerebroventricular routes. Potential sexual dimorphism in the contribution of adrenergic systems to persistent COMT-dependent pain was also assessed.
Results demonstrated that male and female rats receiving sustained OR486 exhibited COMT-dependent mechanical and thermal hypersensitivity, persisting for 2 weeks. In contrast, adrenalectomized rats failed to develop OR486-induced hypersensitivity. Furthermore, intraplantar, but not intrathecal or intracerebroventricular, administration of the nonselective βAR antagonist propranolol, β2AR antagonist ICI118,551, or β3AR antagonist SR59230A blocked OR486-induced hypersensitivity. These findings demonstrate the importance of peripheral β2- and β3ARs in mediating persistent pain and suggest that peripherally-acting βAR antagonists may provide an effective treatment option for patients with chronic pain disorders.
Materials and Methods
Subjects
Adult male and female Sprague–Dawley rats (N = 24 intact, N = 24 adrenalectomized, and N = 23 sham) were purchased (Charles River Laboratories, USA) for the first set of experiments. For subsequent βAR antagonist experiments, adult male Sprague–Dawley rats (N = 111) were bred in-house. Rats weighed between 200 and 400 g for all experimental studies. Rats had ad libitum access to standard laboratory chow and water. Adrenalectomized rats were provided with saline water (0.9%) to compensate for the loss of sodium in urine due to the absence of aldosterone. All animal procedures were approved by the Institutional Animal Care and Use Committee at the University of North Carolina at Chapel Hill. Although rodent models of pain only partially correlate with human conditions, rats were chosen for these experiments because an extensive body of literature exists regarding nociceptive pathways and behavior in this species and because rat pain behavior assays are readily available and well characterized.56–58 
General Experimental Conditions
First, the effects of sustained COMT inhibition on hypersensitivity were evaluated in intact rats receiving the COMT inhibitor OR486 or vehicle systemically for 14 days via a 2002 Alzet Osmotic Pump (Durect Corporation, USA). Next, the contribution of peripheral adrenergic systems to persistent OR486-induced hypersensitivity was evaluated in adrenalectomized rats lacking peripheral epinephrine or sham rats receiving OR486 or vehicle systemically for 14 days via an osmotic pump. Finally, the contribution of peripheral, spinal, and supraspinal βARs to persistent OR486-induced hypersensitivity was evaluated in separate groups of intact rats receiving intraplantar, intrathecal, or intracerebroventricular βAR antagonists alongside systemic delivery of OR486 or vehicle for 14 days via an osmotic pump. The βAR antagonists were delivered via a catheter attached to a separate 2002 Alzet Osmotic Pump.
Animals were handled and habituated to the experimenter and environment for 4 days before testing. Responses to punctuate mechanical and thermal stimuli were assessed in intact and adrenalectomized animals 1 day before and on days 1, 3, 5, 7, 9, 11, and 13 after pump implantation. For βAR antagonist experiments, pain behaviors were assessed 1 day before and on days 2, 4, 6, 8, 10, 12, and 14 after pump implantation. The rest day between surgery and testing allowed animals to fully recover from catheter implantation. On baseline and testing days, rats were habituated to the mechanical and thermal testing environments for 10 to 15 min. Although we were unable to eliminate all environmental factors (e.g., season, humidity, and noise) from this study, we minimized others (e.g., experimenter consistency, testing time of day, and cage density) that were in our control.59,60  Animals were randomly assigned to groups; were tested by a single, blinded experimenter at a consistent time of day (morning); and were housed with one to two other rats. The primary outcome reported in this study is behavioral changes, in the form of mechanical allodynia, mechanical hyperalgesia, and thermal hyperalgesia, which are described in detail below under their respective subtitles.
Drug Preparation
OR486 (Tocris) was dissolved in a 5:3:2 ratio of dimethylsulfoxide, 0.9% saline, and ethanol.32  For peripheral experiments, βAR antagonists propranolol hydrochloride (Tocris), ICI-118,511 (Tocris), and SR59230A (Tocris) were each dissolved in 5:3:2 ratios of dimethylsulfoxide, 0.9% saline, and ethanol. For intrathecal and intracerebroventricular experiments, βAR antagonists were dissolved in 0.9% saline. Drug solutions were injected into pumps, which were placed in 15-ml conical tubes containing sterile 0.9% saline and primed overnight in a dry heat bath (Lab Armor, USA) at 37°C. All pumps (other than those for intrathecal delivery) were attached to corresponding catheters before priming. Subcutaneous delivery of OR486 was at a constant rate of 15 mg · kg−1 · day−1 for a 2-week period. Peripheral delivery of propranolol hydrochloride was at 9 mg · kg−1 · day−1, ICI-118,511 was at 1.5 mg · kg−1 · day−1, and SR59230A was at 1.67 mg · kg−1 · day−1. Intrathecal delivery of propranolol hydrochloride was at 50 μg/day for the low-dose experiments and 100 μg/day for the high-dose experiments, ICI-118,511 was at 30 μg/day, and SR59230A was at 20 μg/day. Intracerebroventricular delivery of propranolol hydrochloride was at 50 μg/day for the low-dose experiments and 100 μg/day for the high-dose experiments; ICI-118,511 delivery was at 30 μg/day, and SR59230A delivery was at 20 μg/day.
Surgical Procedures
For all surgical procedures, rats were anesthetized by isoflurane inhalation (5% induction, 1.5 to 5% maintenance). Incision sites were shaved and disinfected with ethanol and betadine. Sterile technique was employed throughout the duration of all procedures according to Institutional Animal Care and Use Committee requirements. Stainless steel wound clips (Braintree Scientific, USA) were used to close the wounds.
For systemic delivery of OR486, a small incision was made over the left shoulder blade of the rat. Hemostats were used to create a small subcutaneous pocket in which the pump was placed.
For intraplantar delivery of βAR antagonists, a modified version of the protocol published by Haddad and Adams61  was used. Pumps were attached to a 15-cm, Y-shaped, bifurcated 3-French silicone catheter (SAI Infusion Technologies, USA). The pump was implanted subcutaneously over the right shoulder blade, and a stainless steel 10-gauge × 20-cm semiblunt tip trocar (SAI Infusion Technologies) was used to subcutaneously route the catheter ends to incisions made at either hind paw. The catheter ends were attached to the plantar fascia using 4-0 silk sutures (Oasis Medical, USA).
For intrathecal delivery62  of βAR antagonists, a small incision was made on the nape of the neck, and scissors and hemostats were used to lift muscle and expose the atlantooccipital membrane. The membrane was carefully incised using the tip of scissors, causing the escape of cerebrospinal fluid. A 27.3-cm, polyurethane Alzet Short Rat IT Catheter (Durect Corporation) was inserted into the intrathecal space, dorsal to the spinal cord. The other end of the catheter was sutured to the surrounding tissue and attached to the osmotic pump, which was subcutaneously implanted over the right shoulder blade. Four animals did not wake up after intrathecal surgery. These animals were replaced in future intrathecal groups to account for the decrease in sample size.
For intracerebroventricular delivery63  of βAR antagonists, pumps were attached to a 38-gauge stainless steel cannula via a short vinyl catheter (Alzet Brain Infusion Kit 2; Durect Corporation). The cannula was implanted into the right lateral ventricle (from the bregma: −0.8 mm anteroposterior, −1.6 mm mediolateral, −5 mm dorsoventral) and was cemented to two anchoring screws on the skull. The attached pump was subcutaneously implanted over the right shoulder blade.
Assessment of Behavioral Responses to Mechanical and Thermal Stimuli
Paw withdrawal threshold was assessed using the von Frey up–down method.64  Nine calibrated and logarithmically spaced von Frey monofilaments (bending forces: 0.40, 0.68, 1.1, 2.1, 3.4, 5.7, 8.4, 13.2, and 15.0 g; Stoelting, USA) were applied to the plantar hind paw. First, the middle filament (3.4 g) was applied to the hind paw for 3 s. If the rat responded with a withdrawal, an incrementally lower filament was applied. In the absence of a withdrawal, an incrementally higher filament was applied. A series of six total responses were recorded for each paw. Results were entered into the Paw Flick module within the National Instruments LabVIEW 2.0 software (LabVIEW, USA), which uses a logarithmic algorithm to determine the gram-force value that would elicit paw withdrawal in 50% of trials (10(Xf + kδ)/10,000, where Xf = value [in log units] of the final von Frey hair used; k = tabular value of positive and negative responses, and δ = mean difference [in log units] between stimuli). Mechanical allodynia was defined as a heightened response to a normally innocuous stimulus, as determined by a decrease in paw withdrawal threshold.
Mechanical hyperalgesia was assessed using a 15.0-g von Frey filament. This filament was chosen as a normally noxious stimulus, as it has a gram-force value well over the 50% withdraw threshold for animals tested in this study. The filament was applied to the hind paw 10 times for a duration of 1 s, with an interstimulus interval of 1 s.32  The number of paw withdrawals (which could range from 0 to 10) was recorded for each hind paw at each time point. Mechanical hyperalgesia was defined as an increase in the number of paw withdrawals in response to a normally noxious mechanical stimulus.
Thermal hyperalgesia was assessed using the Hargreaves method.65  Animals were placed in plexiglass chambers, and a radiant beam of light was applied to the hind paw through a glass floor heated to 30°C. Paw withdrawal latencies were recorded in duplicate per paw. If the second latency recorded was not within ±4 s of the first, a third measure was recorded. The two latencies closest in value were averaged to determine overall latency to withdrawal. Thermal behavioral data are reported in text and figures as the difference in paw withdrawal latency from baseline (day 0). Thermal hyperalgesia was defined as a decrease in paw withdrawal latency in response to a noxious thermal stimulus.
Statistical Analyses
Sample sizes were selected based on their ability in previous, similarly structured rat studies to accurately demonstrate behavioral differences between groups.30–32  Mechanical allodynia, mechanical hyperalgesia, and thermal hyperalgesia data were analyzed by 2-way ANOVA (for group × time). In ANOVA analyses, groups correspond to the separate groups on the graph of interest, as denoted by different symbols and names (e.g., groups in fig. 1 = vehicle and OR486). Post hoc comparisons were performed using the Bonferroni test, which corrected for multiple comparisons. Statistical significance was defined as P < 0.05. All statistical analyses were performed using GraphPad Prism (GraphPad Software, USA).
Fig. 1.
Sustained administration of the catecholamine-O-methyltransferase inhibitor OR486 leads to mechanical and thermal hypersensitivity. Compared to vehicle, sustained systemic OR486 administration produces (A) mechanical allodynia, (B) mechanical hyperalgesia, and (C) thermal hyperalgesia. N = 12 (6 males and 6 females) per group. Data are expressed as mean ± SEM. ***P < 0.001, **P < 0.01 different from vehicle. BL = baseline; Veh = vehicle.
Sustained administration of the catecholamine-O-methyltransferase inhibitor OR486 leads to mechanical and thermal hypersensitivity. Compared to vehicle, sustained systemic OR486 administration produces (A) mechanical allodynia, (B) mechanical hyperalgesia, and (C) thermal hyperalgesia. N = 12 (6 males and 6 females) per group. Data are expressed as mean ± SEM. ***P < 0.001, **P < 0.01 different from vehicle. BL = baseline; Veh = vehicle.
Fig. 1.
Sustained administration of the catecholamine-O-methyltransferase inhibitor OR486 leads to mechanical and thermal hypersensitivity. Compared to vehicle, sustained systemic OR486 administration produces (A) mechanical allodynia, (B) mechanical hyperalgesia, and (C) thermal hyperalgesia. N = 12 (6 males and 6 females) per group. Data are expressed as mean ± SEM. ***P < 0.001, **P < 0.01 different from vehicle. BL = baseline; Veh = vehicle.
×
Results
Sustained COMT Inhibition Produces Persistent Pain
Genetic and pharmacologic alterations resulting in reduced COMT activity are associated with increased experimental pain and likelihood of developing chronic pain disorders. Acute administration of the COMT inhibitor OR486 results in enhanced mechanical and thermal hypersensitivity in rats.32  To evaluate the effects of sustained COMT inhibition on hypersensitivity, responses to mechanical and thermal stimuli were measured in separate groups of rats receiving systemic OR486 (15 mg · kg−1 · day−1) or vehicle over a 2-week period. Compared to rats receiving vehicle, those receiving OR486 exhibited mechanical allodynia (group: P < 0.0001; group × day: P = 0.0043; fig. 1A), mechanical hyperalgesia (group: P < 0.0001; group × day: P = 0.0109; fig. 1B), and thermal hyperalgesia (group: P < 0.0001; group × day: P < 0.0001; fig. 1C) beginning on day 1 and lasting throughout the duration of the experiment. Sexual dimorphism was not observed, as both male and female rats developed mechanical allodynia (male group: P < 0.0001; female group: P < 0.0001; fig. 1A, Supplemental Digital Content 1, http://links.lww.com/ALN/B262), mechanical hyperalgesia (male group, P < 0.0053; female group: P < 0.0001; fig. 1B, Supplemental Digital Content 1, http://links.lww.com/ALN/B262), and thermal hyperalgesia (male group: P < 0.0001; female group: P < 0.0001; fig. 1C, Supplemental Digital Content 1, http://links.lww.com/ALN/B262). See figure 1, Supplemental Digital Content 1 (http://links.lww.com/ALN/B262), for all sexual dimorphism data in intact rats.
Adrenalectomized Rats Fail to Develop Persistent COMT-dependent Pain
Previous work has demonstrated that acute COMT-dependent pain is mediated via β2- and β3ARs, which are located in peripheral, spinal, and supraspinal regions where they could potentially drive pain transmission. To evaluate the potential contribution of peripheral adrenergic systems to COMT-dependent pain, separate groups of adrenalectomized rats (lacking peripheral epinephrine) or sham surgery rats received systemic OR486 (15 mg · kg−1 · day−1) or vehicle over a 2-week period, and responses to mechanical and thermal stimuli were measured. Compared to sham rats receiving vehicle, those receiving OR486 developed mechanical allodynia (group: P < 0.0001; group × day: P < 0.0001; fig. 2A), mechanical hyperalgesia (group: P < 0.0001; group × day: P = 0.0044; fig. 2B), and thermal hyperalgesia (group: P = 0.0005; group × day: P < 0.0001; fig. 2C). In contrast, adrenalectomized rats did not develop mechanical allodynia, mechanical hyperalgesia, or thermal hyperalgesia.
Fig. 2.
Adrenalectomized (Adx) rats fail to develop OR486-induced hypersensitivity. In Sham (Shm), but not Adx, animals, sustained systemic OR486 administration produces (A) mechanical allodynia, (B) mechanical hyperalgesia, and (C) thermal hyperalgesia. N = 11 (5 males and 6 females) for Shm/vehicle (Veh) and N = 12 (6 males and 6 females) for all other groups. Data are expressed as mean ± SEM. ***P < 0.001, **P < 0.01, *P < 0.05 different from Shm/Veh. BL = Baseline.
Adrenalectomized (Adx) rats fail to develop OR486-induced hypersensitivity. In Sham (Shm), but not Adx, animals, sustained systemic OR486 administration produces (A) mechanical allodynia, (B) mechanical hyperalgesia, and (C) thermal hyperalgesia. N = 11 (5 males and 6 females) for Shm/vehicle (Veh) and N = 12 (6 males and 6 females) for all other groups. Data are expressed as mean ± SEM. ***P < 0.001, **P < 0.01, *P < 0.05 different from Shm/Veh. BL = Baseline.
Fig. 2.
Adrenalectomized (Adx) rats fail to develop OR486-induced hypersensitivity. In Sham (Shm), but not Adx, animals, sustained systemic OR486 administration produces (A) mechanical allodynia, (B) mechanical hyperalgesia, and (C) thermal hyperalgesia. N = 11 (5 males and 6 females) for Shm/vehicle (Veh) and N = 12 (6 males and 6 females) for all other groups. Data are expressed as mean ± SEM. ***P < 0.001, **P < 0.01, *P < 0.05 different from Shm/Veh. BL = Baseline.
×
Sexual dimorphism was not observed, as both male and female sham rats developed mechanical allodynia (male group: P < 0.0001; female group: P < 0.0001; fig. 2A, Supplemental Digital Content 1, http://links.lww.com/ALN/B262), mechanical hyperalgesia (male group: P = 0.0053; female group: P < 0.0001; fig. 2B, Supplemental Digital Content 1, http://links.lww.com/ALN/B262), and thermal hyperalgesia (male group: P < 0.0001; female group: P < 0.0001; fig. 2C, Supplemental Digital Content 1, http://links.lww.com/ALN/B262). Both male and female adrenalectomized rats failed to develop mechanical allodynia (fig. 2D, Supplemental Digital Content 1, http://links.lww.com/ALN/B262), mechanical hyperalgesia (fig. 2E, Supplemental Digital Content 1, http://links.lww.com/ALN/B262), and thermal hyperalgesia (fig. 2F, Supplemental Digital Content 1, http://links.lww.com/ALN/B262). See figure 2, Supplemental Digital Content 1 (http://links.lww.com/ALN/B262), for all sexual dimorphism data in sham and adrenalectomized rats.
Peripheral βAR Antagonist Administration Prevents the Development of Persistent COMT-dependent Pain
Adrenalectomized rats failed to develop persistent hypersensitivity after COMT inhibition, suggesting a peripheral adrenergic site of action. In order to further investigate this hypothesis, pharmacological methods were used to determine the contribution of peripheral, spinal, and supraspinal βARs to persistent COMT-dependent pain. First, the contribution of peripheral βARs to mechanical and thermal hypersensitivity was evaluated in separate groups of rats receiving sustained intraplantar administration of propranolol (9 mg · kg−1 · day−1), ICI-118,551 (1.5 mg · kg−1 · day−1), SR59230A (1.67 mg · kg−1 · day−1), or vehicle alongside sustained systemic administration of OR486 (15 mg · kg−1 · day−1) or vehicle over a 2-week period. Peripheral antagonist doses were selected based on the results from a preliminary study that evaluated the ability of three different doses per antagonist to reduce or block COMT-dependent pain (fig. 3).
Fig. 3.
Peripheral administration of β-adrenergic receptor (βAR) antagonists blocks OR486-induced hypersensitivity. Peripheral delivery of the nonselective βAR antagonist propranolol (Prop) alongside sustained systemic OR486 administration prevents (A) mechanical allodynia and (D) mechanical hyperalgesia but does not alter (G) thermal hyperalgesia. Similarly, peripheral delivery of the β2AR antagonist ICI-118,551 (ICI) alongside sustained systemic OR486 administration prevents (B) mechanical allodynia and (E) mechanical hyperalgesia but does not alter (H) thermal hyperalgesia. Finally, peripheral delivery of the β3AR antagonist SR59230A (SR) alongside sustained systemic OR486 administration prevents (C) mechanical allodynia, (F) mechanical hyperalgesia, and (I) thermal hyperalgesia. N = 9 per group. Data are expressed as mean ± SEM. ***P < 0.001, **P < 0.01, *P < 0.05 different from vehicle (Veh)/Veh. BL = Baseline.
Peripheral administration of β-adrenergic receptor (βAR) antagonists blocks OR486-induced hypersensitivity. Peripheral delivery of the nonselective βAR antagonist propranolol (Prop) alongside sustained systemic OR486 administration prevents (A) mechanical allodynia and (D) mechanical hyperalgesia but does not alter (G) thermal hyperalgesia. Similarly, peripheral delivery of the β2AR antagonist ICI-118,551 (ICI) alongside sustained systemic OR486 administration prevents (B) mechanical allodynia and (E) mechanical hyperalgesia but does not alter (H) thermal hyperalgesia. Finally, peripheral delivery of the β3AR antagonist SR59230A (SR) alongside sustained systemic OR486 administration prevents (C) mechanical allodynia, (F) mechanical hyperalgesia, and (I) thermal hyperalgesia. N = 9 per group. Data are expressed as mean ± SEM. ***P < 0.001, **P < 0.01, *P < 0.05 different from vehicle (Veh)/Veh. BL = Baseline.
Fig. 3.
Peripheral administration of β-adrenergic receptor (βAR) antagonists blocks OR486-induced hypersensitivity. Peripheral delivery of the nonselective βAR antagonist propranolol (Prop) alongside sustained systemic OR486 administration prevents (A) mechanical allodynia and (D) mechanical hyperalgesia but does not alter (G) thermal hyperalgesia. Similarly, peripheral delivery of the β2AR antagonist ICI-118,551 (ICI) alongside sustained systemic OR486 administration prevents (B) mechanical allodynia and (E) mechanical hyperalgesia but does not alter (H) thermal hyperalgesia. Finally, peripheral delivery of the β3AR antagonist SR59230A (SR) alongside sustained systemic OR486 administration prevents (C) mechanical allodynia, (F) mechanical hyperalgesia, and (I) thermal hyperalgesia. N = 9 per group. Data are expressed as mean ± SEM. ***P < 0.001, **P < 0.01, *P < 0.05 different from vehicle (Veh)/Veh. BL = Baseline.
×
Compared to rats receiving vehicle, those receiving sustained intraplantar administration of the nonselective βAR antagonist propranolol, the β2AR antagonist ICI-118,511, or the β3AR antagonist SR59230A alongside systemic OR486 did not develop mechanical allodynia (group: fig. 3A, P < 0.0001; fig. 3B, P < 0.0001; fig. 3C, P < 0.0001) or mechanical hyperalgesia (group: fig. 3D, P < 0.0001; fig. 3E, P < 0.0001; fig. 3F, P < 0.0001). Rats receiving sustained intraplantar administration of the β3AR antagonist SR59230A also did not develop OR486-induced thermal hyperalgesia (group: fig. 3I, P < 0.0001). In contrast, rats receiving propranolol (fig. 3G) or ICI-118,551 (fig. 3H) alongside OR486 exhibited a 15% decrease in paw withdrawal latency from baseline, similar to rats receiving vehicle. Animals receiving sustained intraplantar administration of βAR antagonists alongside systemic vehicle failed to develop mechanical allodynia (fig. 3A, Supplemental Digital Content 1, http://links.lww.com/ALN/B262), mechanical hyperalgesia (fig. 3D, Supplemental Digital Content 1, http://links.lww.com/ALN/B262), or thermal hyperalgesia (fig. 3G, Supplemental Digital Content 1, http://links.lww.com/ALN/B262). See figure 3, Supplemental Digital Content 1 (http://links.lww.com/ALN/B262), for control data demonstrating no effect of antagonists on hypersensitivity irrespective of administration route.
Intrathecal βAR Antagonist Administration Does Not Alter Persistent COMT-dependent Pain
Next, the contribution of spinal βARs to mechanical and thermal hypersensitivity was evaluated in separate groups of rats receiving sustained intrathecal administration of propranolol (50 μg/day), ICI-118,551 (30 μg/day), SR59230A (20 μg/day), or vehicle alongside sustained systemic administration of OR486 (15 mg · kg−1 · day−1) or vehicle over a 2-week period (fig. 4). Intrathecal delivered antagonist doses were selected based on their ability to block hypersensitivity or pain-relevant behaviors in other rat models when administered intrathecally.66–68  Similar to animals receiving vehicle, those receiving sustained intrathecal administration of the nonselective βAR antagonist propranolol, the β2AR antagonist ICI-118,511, or the β3AR antagonist SR59230A alongside systemic OR486 exhibited mechanical allodynia (group: fig. 4A, P < 0.0001; fig. 4B, P < 0.0001; fig. 4C, P < 0.0001), mechanical hyperalgesia (group: fig. 4D, P = 0.0002; fig. 4E, P < 0.0001; fig. 4F, P = 0.0018), and thermal hyperalgesia (group: fig. 4G, P < 0.0001; fig. 4H, P < 0.0001; fig. 4I, P < 0.0001). Animals receiving sustained intrathecal administration of βAR antagonists alongside systemic vehicle failed to develop mechanical allodynia (fig. 3B, Supplemental Digital Content 1, http://links.lww.com/ALN/B262), mechanical hyperalgesia (fig. 3E, Supplemental Digital Content 1, http://links.lww.com/ALN/B262), or thermal hyperalgesia (fig. 3H, Supplemental Digital Content 1, http://links.lww.com/ALN/B262). Animals receiving SR59230A alongside vehicle did exhibit transient elevations in paw withdrawal threshold on days 2 (vehicle/vehicle 4.47 ± 0.63 vs. vehicle/SR59230A 10.80 ± 3.26, mean ± SEM) and 10 (vehicle/vehicle 3.50 ± 0.73 vs. vehicle/SR59230A 10.97 ± 3.13) likely due to higher baseline values (vehicle/vehicle 4.76 ± 0.55 vs. vehicle/SR59230A 8.54 ± 2.59) and increased intergroup variability as compared to control animals (fig. 3B, Supplemental Digital Content 1, http://links.lww.com/ALN/B262).
Fig. 4.
Intrathecal administration of β-adrenergic receptor (βAR) antagonists does not alter OR486-induced hypersensitivity. Intrathecal delivery of the nonselective βAR antagonist propranolol (prop) (A, D, G), the β2AR antagonist ICI-118,551 (ICI) (B, E, H), or the β3AR antagonist SR59230A (SR) (C, F, I) alongside sustained systemic OR486 administration does not alter mechanical or thermal sensitivity. N = 4 per group. Data are expressed as mean ± SEM. ***P < 0.001, **P < 0.01, *P < 0.05 different from vehicle (Veh)/Veh. BL = Baseline.
Intrathecal administration of β-adrenergic receptor (βAR) antagonists does not alter OR486-induced hypersensitivity. Intrathecal delivery of the nonselective βAR antagonist propranolol (prop) (A, D, G), the β2AR antagonist ICI-118,551 (ICI) (B, E, H), or the β3AR antagonist SR59230A (SR) (C, F, I) alongside sustained systemic OR486 administration does not alter mechanical or thermal sensitivity. N = 4 per group. Data are expressed as mean ± SEM. ***P < 0.001, **P < 0.01, *P < 0.05 different from vehicle (Veh)/Veh. BL = Baseline.
Fig. 4.
Intrathecal administration of β-adrenergic receptor (βAR) antagonists does not alter OR486-induced hypersensitivity. Intrathecal delivery of the nonselective βAR antagonist propranolol (prop) (A, D, G), the β2AR antagonist ICI-118,551 (ICI) (B, E, H), or the β3AR antagonist SR59230A (SR) (C, F, I) alongside sustained systemic OR486 administration does not alter mechanical or thermal sensitivity. N = 4 per group. Data are expressed as mean ± SEM. ***P < 0.001, **P < 0.01, *P < 0.05 different from vehicle (Veh)/Veh. BL = Baseline.
×
To confirm that intrathecal βAR antagonists were unable to block OR486-induced hypersensitivity, we performed a duplicate set of experiments using a higher dose of the nonselective βAR antagonist propranolol (100 μg/day). Similar to the original dose, intrathecal administration of the higher dose did not block OR486-induced mechanical allodynia (group: P < 0.0001; fig. 4A, Supplemental Digital Content 1, http://links.lww.com/ALN/B262), mechanical hyperalgesia (group: P = 0.0011; fig. 4D, Supplemental Digital Content 1, http://links.lww.com/ALN/B262), or thermal hyperalgesia (group: P < 0.0001; fig. 4G, Supplemental Digital Content 1, http://links.lww.com/ALN/B262). See figure 4, Supplemental Digital Content 1 (http://links.lww.com/ALN/B262), for all intrathecal high-dose propranolol data.
Intracerebroventricular βAR Antagonist Administration Does Not Alter Persistent COMT-dependent Pain
Finally, the contribution of supraspinal βARs to mechanical and thermal hypersensitivity was evaluated in separate groups of rats receiving sustained intracerebroventricular administration of propranolol (50 μg/day), ICI-118,551 (30 μg/day), SR59230A (20 μg/day), or vehicle alongside sustained systemic administration of OR486 (15 mg · kg−1 · day−1) or vehicle over a 2-week period (fig. 5). Intracerebroventricular antagonist doses were selected based on their ability to block hypersensitivity or related behaviors in other rat models.66–68  Similar to animals receiving vehicle, those receiving sustained intracerebroventricular administration of the nonselective βAR antagonist propranolol, the β2AR antagonist ICI-118,511, or the β3AR antagonist SR59230A alongside systemic OR486 exhibited mechanical allodynia (group: fig. 5A, P < 0.0001; fig. 5B, P < 0.0001; fig. 5C, P < 0.0001), mechanical hyperalgesia (group: fig. 5D, P < 0.0001; fig. 5E, P < 0.0001; fig. 5F, P < 0.0001), and thermal hyperalgesia (group: fig. 5G, P < 0.0001; fig. 5H, P < 0.0001; fig. 5I, P < 0.0001). Animals receiving sustained intracerebroventricular administration of βAR antagonists alongside systemic vehicle failed to develop mechanical allodynia (fig. 3C, Supplemental Digital Content 1, http://links.lww.com/ALN/B262), mechanical hyperalgesia (fig. 3F, Supplemental Digital Content 1, http://links.lww.com/ALN/B262), or thermal hyperalgesia (fig. 3I, Supplemental Digital Content 1, http://links.lww.com/ALN/B262). Animals receiving SR59230A alongside vehicle did exhibit transient elevations in paw withdrawal frequency on days 2 (vehicle/vehicle 1.88 ± 0.40 vs. vehicle/SR59230A 4.62 ± 0.86) and 8 (vehicle/vehicle 2.00 ± 0.46 vs. vehicle/SR59230A 5.00 ± 1.20) likely due to increased intergroup variability as compared to control animals (fig. 3F, Supplemental Digital Content 1, http://links.lww.com/ALN/B262).
Fig. 5.
Intracerebroventricular administration of β-adrenergic receptor (βAR) antagonists does not alter OR486-induced hypersensitivity. Supraspinal delivery of the nonselective βAR antagonist propranolol (prop) (A, D, G), β2AR antagonist ICI-118,551 (ICI) (B, E, H), or the β3AR antagonist SR59230A (SR) (C, F, I) alongside sustained systemic OR486 administration does not alter mechanical or thermal sensitivity. N = 4–5 per group. Data are expressed as mean ± SEM. ***P < 0.001, **P < 0.01, *P < 0.05 different from vehicle (Veh)/Veh. BL = Baseline.
Intracerebroventricular administration of β-adrenergic receptor (βAR) antagonists does not alter OR486-induced hypersensitivity. Supraspinal delivery of the nonselective βAR antagonist propranolol (prop) (A, D, G), β2AR antagonist ICI-118,551 (ICI) (B, E, H), or the β3AR antagonist SR59230A (SR) (C, F, I) alongside sustained systemic OR486 administration does not alter mechanical or thermal sensitivity. N = 4–5 per group. Data are expressed as mean ± SEM. ***P < 0.001, **P < 0.01, *P < 0.05 different from vehicle (Veh)/Veh. BL = Baseline.
Fig. 5.
Intracerebroventricular administration of β-adrenergic receptor (βAR) antagonists does not alter OR486-induced hypersensitivity. Supraspinal delivery of the nonselective βAR antagonist propranolol (prop) (A, D, G), β2AR antagonist ICI-118,551 (ICI) (B, E, H), or the β3AR antagonist SR59230A (SR) (C, F, I) alongside sustained systemic OR486 administration does not alter mechanical or thermal sensitivity. N = 4–5 per group. Data are expressed as mean ± SEM. ***P < 0.001, **P < 0.01, *P < 0.05 different from vehicle (Veh)/Veh. BL = Baseline.
×
To confirm that intracerebroventricular βAR antagonists are unable to block OR486-induced hypersensitivity, we performed a duplicate set of experiments using a higher dose of the nonselective βAR antagonist propranolol (100 μg/day). Similar to the original dose, intracerebroventricular administration of the higher dose did not block OR486-induced mechanical allodynia (group: P < 0.0001; fig. 5A, Supplemental Digital Content 1, http://links.lww.com/ALN/B262), mechanical hyperalgesia (group: P < 0.0001; fig. 5D, Supplemental Digital Content 1, http://links.lww.com/ALN/B262), or thermal hyperalgesia (group: P < 0.0001; fig. 5G, Supplemental Digital Content 1, http://links.lww.com/ALN/B262). See figure 5, Supplemental Digital Content 1 (http://links.lww.com/ALN/B262), for all intracerebroventricular high-dose propranolol data.
Discussion
Although the mechanisms underlying chronic pain disorders are not well described, emerging evidence suggests a role for adrenergic pathways. Employing a rodent model of sustained COMT inhibition that mimics abnormalities in catecholamine signaling observed in patients with these disorders, we demonstrate that COMT-dependent pain is mediated via peripherally, but not spinally or supraspinally, located β2- and β3ARs.
In previous studies, we established a causal link between low COMT and pain. We demonstrated that a single injection of the COMT inhibitor OR486 produces mechanical and thermal hypersensitivity, similar to that produced by intraplantar carrageenan. Subsequent pharmacological studies further demonstrated that the development of acute OR486-induced hypersensitivity requires activation of β2- and β3ARs.30,32  Within hours, administration of OR486 results in increased circulating levels of nitric oxide and the proinflammatory cytokines tumor necrosis factor-α, interleukin-1β, interleukin-6, and chemokine (C-C motif) ligand 2 (CCL2),30  which are nociceptive transmitters implicated in chronic pain. Individuals with fibromyalgia, headache, and TMD exhibit increased levels of these molecules,69–72  which elicit pain by reducing nociceptor firing thresholds.73–83  Nitric oxide and proinflammatory cytokines also elicit pain by working synergistically to potentiate one another’s biosynthesis, as observed in the OR486 model.30 
Here, we utilized a more clinically-relevant model of sustained COMT inhibition, characterized by enhanced sensitivity to noxious stimuli and altered pain-relevant cognitive–affective behaviors that persist over a 2-week period, to determine the site-of -action whereby βARs mediate persistent COMT-dependent pain. The contribution of peripheral adrenergic systems was first examined in adrenalectomized rats. We found that, compared to sham surgery rats, adrenalectomized rats lacking peripheral epinephrine fail to develop OR486-induced mechanical and thermal hypersensitivity. This finding is in line with those from previous studies showing that adrenalectomized rats have blunted hypersensitivity after formalin administration84  or chronic constriction injury.85  Together, these results suggest that peripherally circulating catecholamines contribute to the transmission of hypersensitivity in models of inflammatory and neuropathic pain, as well as chronic pain disorders. This conclusion is further supported by studies that have demonstrated increased urinary catecholamines in patients with myofascial pain10  and increased circulating plasma catecholamines in women with fibromyalgia.9  Of note, adrenalectomy also results in a reduction of circulating corticosterone levels.86,87  Increased corticosterone levels after stress88  or nerve injury89,90  have been implicated in analgesia and pronociception. Thus, future experiments examining peripheral catecholamines should utilize adrenal medullectomized animals or should provide supplemental corticosterone to adrenalectomized animals to rule out corticosterone-mediated effects.
As previous preclinical and clinical studies have reported sex-specific differences in COMT-related phenotypes,91–95  and as males and female rats exhibit different COMT expression patterns,96,97  we examined the contribution of peripheral adrenergic systems to COMT-dependent pain in both sexes. Counter to our expectation, male and female rats exhibited a comparable increase in mechanical and thermal hypersensitivity after sustained systemic OR486 administration, which was blocked by suppressing peripheral adrenergic tone. Despite these findings, future studies and clinical applications related to COMT-dependent pain should continue to consider possible sex-specific effects.
The independent contribution of peripheral, spinal, and supraspinal βARs to persistent COMT-dependent pain was next examined in separate groups of intact rats receiving targeted delivery of the nonselective βAR antagonist propranolol, the β2AR antagonist ICI-118,551, or the β3AR antagonist SR59230A alongside systemic OR486. We found that peripheral, but not spinal or supraspinal, administration of propranolol, ICI-118,511, or SR59230A blocked the development of OR486-induced hypersensitivity throughout the duration of the testing period. While all three antagonists blocked the development of mechanical hypersensitivity, only SR59230A blocked the development of thermal hypersensitivity. These findings significantly extend those from acute COMT inhibition studies,30,32  demonstrating that peripheral β2- and β3ARs both contribute to the development of persistent mechanical hypersensitivity, while peripheral β3ARs independently contribute to the development of persistent thermal hypersensitivity after sustained COMT inhibition.
The peripheral contribution of β2ARs to pain is in line with results from previous studies demonstrating that epinephrine activates β2ARs located on the peripheral terminals of primary afferent nociceptors, increasing their excitability and producing a hyperalgesic state.35–39  Also, elevated plasma norepinephrine activates β2ARs to promote visceral hypersensitivity.38  In humans, variants of the β2AR gene known to influence receptor expression are associated with increased risk of TMD.98 
The contribution of peripheral β3ARs to persistent pain is more novel. Peripherally expressed β3ARs are known for their ability to regulate norepinephrine-induced changes in metabolism and thermoregulation.99  In 2010, it was discovered that β3ARs are expressed on primary afferent nociceptors, where they drive norepinephrine-induced ATP release and contribute to neuropathic pain.54  Recently, β3ARs have also been shown to mediate formalin-induced temporomandibular joint pain.100  In contrast to acute COMT-dependent thermal hypersensitivity, which requires coincident activation of both β2- and β3ARs,32  persistent COMT-dependent thermal hypersensitivity requires independent activation of peripheral β3ARs. Unlike most G-protein–coupled receptors, including β2ARs, β3ARs do not undergo desensitization after agonist stimulation.101,102  Thus, β3ARs are uniquely positioned to stimulate downstream effectors for prolonged periods of time.
In addition to their location on primary afferent nociceptors, β2- and β3ARs are expressed in numerous peripheral cell types, in which they could potentially mediate pain, including immune cells involved in adaptive responses (T cells, mast cells, and macrophages), adipocytes, keratinocytes, and satellite glia. T cells, mast cells, and macrophages are immune cells in the periphery that express βARs and, after their activation by epinephrine or norepinephrine, orchestrate inflammatory responses. Increased catecholamine levels after stress or pharmacologic manipulation led to activation of T cells, increased expression of β2- and β3ARs,49  and production of interleukin-1, interleukin-6, and CCL2.103  T-cell infiltration in the spinal dorsal horn of adult rats has been shown to contribute to hypersensitivity after nerve injury.104,105  In line with these findings, patients with fibromyalgia have more activated T cells circulating in blood compared to healthy controls.106  Epinephrine activates mast cells and stimulates the release of interleukin-1β, interleukin-6, and other proinflammatory cytokines in a β2AR-dependent manner.46  Increased activation of mast cells has been observed in numerous chronic pain disorders, including fibromyalgia, headache, vestibulodynia, and irritable bowel syndrome.107–112  Agonist activation of β2ARs expressed on macrophages in vitro results in activation of intracellular kinases and release of interleukin-6. Further, sustained systemic administration of epinephrine in mice results in β2AR-mediated increases in macrophage activation and interleukin-6 production.47,48 
Adipocytes are cells in the periphery that express both β2- and β3ARs and specialize in storing energy as fat.50  They also interface with immune cells to regulate inflammatory responses.113  Notably, adipocytes produce 30% of the interleukin-6 circulating in the body,114  and studies have shown that activation of β3ARs on adipocytes produces a robust increase in interleukin-6 levels in plasma,115  as well as in tumor necrosis factor-α,116  CCL2,117  and NO118  levels in vitro.
Keratinocytes and satellite glial cells reside near the peripheral terminals and cell bodies, respectively, of primary afferent nociceptors. While a direct link between βAR activation on these cell types and pain has yet to be established, catecholamine-induced activation of keratinocyte β2ARs results in increased intracellular kinase activation and interleukin-6 release.43–45  Similarly, activation of satellite glia by catecholamines results in βAR-mediated increases in intracellular cyclic nucleotides that facilitate neuronal–glial communication.119 
Collectively, these findings demonstrate the importance of β2- and β3ARs located on immunoregulatory cells in the periphery to persistent COMT-dependent pain, accounting for clinical observations that βAR antagonists provide pain relief for patients with functional pain disorders, such as fibromyalgia and TMD,33,34,120  as well as inflammatory conditions, such as arthritis, rosacea, and CRPS.121–124  While these findings seem inconsistent with the ability of antidepressants to alleviate persistent pain by increasing synaptic levels of catecholamines, it is important to note that the analgesic effect of antidepressants is associated with descending inhibition of pain via actions at α2ARs or D2 dopamine receptors in the spinal dorsal horn.125,126  Thus, catecholamines can exert divergent influences on nociception as a function of localization and net influence on neuronal excitability. Future studies are required to identify the specific cell type(s) in the periphery that express βARs and, upon activation, release proinflammatory molecules that initiate persistent hypersensitivity. By determining where, when, and how β2- and β3ARs and their downstream effectors mediate COMT-dependent pain, the field will better understand the diverse nature of catecholamine signaling so that patients suffering from disorders resulting from reduced COMT and/or elevated catecholamines receive the most relevant treatments.
While the studies herein utilized a clinically-relevant rodent model of sustained COMT inhibition, additional mechanistic studies will implement a COMT−/− mouse model in order to more accurately represent the endogenously low levels of COMT activity observed in pain patients. Future studies are also necessary to elucidate the specific cell signaling pathways responsible for the initiation and maintenance of β2- and β3AR-mediated hypersensitivity. Finally, clinical studies are required to evaluate the efficacy of peripheral β2- and β3AR antagonist therapy in patients with chronic pain disorders and related conditions.
In conclusion, we utilized a clinically-relevant animal model that portrays the characteristics of patients with chronic pain disorders to demonstrate that both male and female rats are susceptible to the development of persistent COMT-dependent pain, which is mediated via peripherally located β2- and β3ARs. These findings suggest that peripheral β2- and β3AR antagonist therapy may be an effective option for the treatment of chronic pain disorders, as well as those with overlapping peripheral β-adrenergic mechanisms (e.g., CRPS127 ).
Acknowledgments
The authors thank SAI Infusion Technologies, Libertyville, Illinois, for their assistance with catheter design.
This work was funded by R01 NS072205 to A.G.N. and P01 NS045685 to A.G.N. (National Institutes of Health [NIH]/National Institute of Neurological Disorders and Stroke, Bethesda, Maryland) as well as by the National Center for Advancing Translational Sciences, NIH, through Grant Award UL1TR001111.
Competing Interests
The authors declare no competing interests.
References
Clauw, DJ Fibromyalgia: A clinical review.. JAMA. (2014). 311 1547–55 [Article] [PubMed]
Dzau, VJ, Pizzo, PA Relieving pain in America: Insights from an Institute of Medicine committee.. JAMA. (2014). 312 1507–8 [Article] [PubMed]
Rey, E, Talley, NJ Irritable bowel syndrome: Novel views on the epidemiology and potential risk factors.. Dig Liver Dis. (2009). 41 772–80 [Article] [PubMed]
Slade, GD, Bair, E, Greenspan, JD, Dubner, R, Fillingim, RB, Diatchenko, L, Maixner, W, Knott, C, Ohrbach, R Signs and symptoms of first-onset TMD and sociodemographic predictors of its development: The OPPERA prospective cohort study.. J Pain. (2013). 1412 suppl T20–32.e1 [Article] [PubMed]
Tsang, A, Von Korff, M, Lee, S, Alonso, J, Karam, E, Angermeyer, MC, Borges, GL, Bromet, EJ, Demytteneare, K, de Girolamo, G, de Graaf, R, Gureje, O, Lepine, JP, Haro, JM, Levinson, D, Oakley Browne, MA, Posada-Villa, J, Seedat, S, Watanabe, M Common chronic pain conditions in developed and developing countries: Gender and age differences and comorbidity with depression-anxiety disorders.. J Pain. (2008). 9 883–91 [Article] [PubMed]
Wesselmann, U, Bonham, A, Foster, D Vulvodynia: Current state of the biological science.. Pain. (2014). 155 1696–701 [Article] [PubMed]
Institute of Medicine (U.S.), Committee on Advancing Pain Research Care and Education.: Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. (2011). Washington, DC National Academies Press
Smith, SB, Maixner, DW, Greenspan, JD, Dubner, R, Fillingim, RB, Ohrbach, R, Knott, C, Slade, GD, Bair, E, Gibson, DG, Zaykin, DV, Weir, BS, Maixner, W, Diatchenko, L Potential genetic risk factors for chronic TMD: Genetic associations from the OPPERA case control study.. J Pain. (2011). 1211 suppl T92–101 [Article] [PubMed]
Torpy, DJ, Papanicolaou, DA, Lotsikas, AJ, Wilder, RL, Chrousos, GP, Pillemer, SR Responses of the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis to interleukin-6: A pilot study in fibromyalgia.. Arthritis Rheum. (2000). 43 872–80 [Article] [PubMed]
Evaskus, DS, Laskin, DM A biochemical measure of stress in patients with myofascial pain-dysfunction syndrome.. J Dent Res. (1972). 51 1464–6 [Article] [PubMed]
Perry, F, Heller, PH, Kamiya, J, Levine, JD Altered autonomic function in patients with arthritis or with chronic myofascial pain.. Pain. (1989). 39 77–84 [Article] [PubMed]
Marbach, JJ, Levitt, M Erythrocyte catechol-O-methyltransferase activity in facial pain patients.. J Dent Res. (1976). 55 711 [Article] [PubMed]
Smith, SB, Reenilä, I, Männistö, PT, Slade, GD, Maixner, W, Diatchenko, L, Nackley, AG Epistasis between polymorphisms in COMT, ESR1, and GCH1 influences COMT enzyme activity and pain.. Pain. (2014). 155 2390–9 [Article] [PubMed]
Männistö, PT, Kaakkola, S Catechol-O-methyltransferase (COMT): Biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors.. Pharmacol Rev. (1999). 51 593–628 [PubMed]
Capellino, S, Cosentino, M, Wolff, C, Schmidt, M, Grifka, J, Straub, RH Catecholamine-producing cells in the synovial tissue during arthritis: Modulation of sympathetic neurotransmitters as new therapeutic target.. Ann Rheum Dis. (2010). 69 1853–60 [Article] [PubMed]
Flierl, MA, Rittirsch, D, Huber-Lang, M, Sarma, JV, Ward, PA Catecholamines-crafty weapons in the inflammatory arsenal of immune/inflammatory cells or opening pandora’s box?. Mol Med. (2008). 14 195–204 [PubMed]
Harden, RN, Rudin, NJ, Bruehl, S, Kee, W, Parikh, DK, Kooch, J, Duc, T, Gracely, RH Increased systemic catecholamines in complex regional pain syndrome and relationship to psychological factors: A pilot study.. Anesth Analg. (2004). 99 1478–85 [Article] [PubMed]
Lotta, T, Vidgren, J, Tilgmann, C, Ulmanen, I, Melén, K, Julkunen, I, Taskinen, J Kinetics of human soluble and membrane-bound catechol O-methyltransferase: A revised mechanism and description of the thermolabile variant of the enzyme.. Biochemistry. (1995). 34 4202–10 [Article] [PubMed]
Nackley, AG, Shabalina, SA, Tchivileva, IE, Satterfield, K, Korchynskyi, O, Makarov, SS, Maixner, W, Diatchenko, L Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure.. Science. (2006). 314 1930–3 [Article] [PubMed]
Barbosa, FR, Matsuda, JB, Mazucato, M, de Castro França, S, Zingaretti, SM, da Silva, LM, Martinez-Rossi, NM, Júnior, MF, Marins, M, Fachin, AL Influence of catechol-O-methyltransferase (COMT) gene polymorphisms in pain sensibility of Brazilian fibromyalgia patients.. Rheumatol Int. (2012). 32 427–30 [Article] [PubMed]
Cohen, H, Neumann, L, Glazer, Y, Ebstein, RP, Buskila, D The relationship between a common catechol-O-methyltransferase (COMT) polymorphism val(158) met and fibromyalgia.. Clin Exp Rheumatol. (2009). 275 suppl 56 S51–6 [PubMed]
Gürsoy, S, Erdal, E, Herken, H, Madenci, E, Alaşehirli, B, Erdal, N Significance of catechol-O-methyltransferase gene polymorphism in fibromyalgia syndrome.. Rheumatol Int. (2003). 23 104–7 [PubMed]
Matsuda, JB, Barbosa, FR, Morel, LJ, França, Sde C, Zingaretti, SM, da Silva, LM, Pereira, AM, Marins, M, Fachin, AL Serotonin receptor (5-HT 2A) and catechol-O-methyltransferase (COMT) gene polymorphisms: Triggers of fibromyalgia?. Rev Bras Reumatol. (2010). 50 141–9 [Article] [PubMed]
Vargas-Alarcón, G, Fragoso, JM, Cruz-Robles, D, Vargas, A, Vargas, A, Lao-Villadóniga, JI, García-Fructuoso, F, Ramos-Kuri, M, Hernández, F, Springall, R, Bojalil, R, Vallejo, M, Martínez-Lavín, M Catechol-O-methyltransferase gene haplotypes in Mexican and Spanish patients with fibromyalgia.. Arthritis Res Ther. (2007). 9 R110 [Article] [PubMed]
Diatchenko, L, Slade, GD, Nackley, AG, Bhalang, K, Sigurdsson, A, Belfer, I, Goldman, D, Xu, K, Shabalina, SA, Shagin, D, Max, MB, Makarov, SS, Maixner, W Genetic basis for individual variations in pain perception and the development of a chronic pain condition.. Hum Mol Genet. (2005). 14 135–43 [Article] [PubMed]
Zubieta, JK, Heitzeg, MM, Smith, YR, Bueller, JA, Xu, K, Xu, Y, Koeppe, RA, Stohler, CS, Goldman, D COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor.. Science. (2003). 299 1240–3 [Article] [PubMed]
Mobascher, A, Brinkmeyer, J, Thiele, H, Toliat, MR, Steffens, M, Warbrick, T, Musso, F, Wittsack, HJ, Saleh, A, Schnitzler, A, Winterer, G The val158met polymorphism of human catechol-O-methyltransferase (COMT) affects anterior cingulate cortex activation in response to painful laser stimulation.. Mol Pain. (2010). 6 32 [Article] [PubMed]
Rakvåg, TT, Klepstad, P, Baar, C, Kvam, TM, Dale, O, Kaasa, S, Krokan, HE, Skorpen, F The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients.. Pain. (2005). 116 73–8 [Article] [PubMed]
Desmeules, J, Chabert, J, Rebsamen, M, Rapiti, E, Piguet, V, Besson, M, Dayer, P, Cedraschi, C Central pain sensitization, COMT Val158Met polymorphism, and emotional factors in fibromyalgia.. J Pain. (2014). 15 129–35 [Article] [PubMed]
Hartung, JE, Ciszek, BP, Nackley, AG β2- and β3-adrenergic receptors drive COMT-dependent pain by increasing production of nitric oxide and cytokines.. Pain. (2014). 155 1346–55 [Article] [PubMed]
Kline, RHt, Exposto, FG, O’Buckley, SC, Westlund, KN, Nackley, AG Catechol-O-methyltransferase inhibition alters pain and anxiety-related volitional behaviors through activation of beta-adrenergic receptors in the rat.. Neuroscience. (2015). 290 561–9 [Article] [PubMed]
Nackley, AG, Tan, KS, Fecho, K, Flood, P, Diatchenko, L, Maixner, W Catechol-O-methyltransferase inhibition increases pain sensitivity through activation of both beta2- and beta3-adrenergic receptors.. Pain. (2007). 128 199–208 [Article] [PubMed]
Light, KC, Bragdon, EE, Grewen, KM, Brownley, KA, Girdler, SS, Maixner, W Adrenergic dysregulation and pain with and without acute beta-blockade in women with fibromyalgia and temporomandibular disorder.. J Pain. (2009). 10 542–52 [Article] [PubMed]
Tchivileva, IE, Lim, PF, Smith, SB, Slade, GD, Diatchenko, L, McLean, SA, Maixner, W Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: A randomized, double-blind, placebo-controlled, crossover pilot study.. Pharmacogenet Genomics. (2010). 20 239–48 [PubMed]
Aley, KO, Martin, A, McMahon, T, Mok, J, Levine, JD, Messing, RO Nociceptor sensitization by extracellular signal-regulated kinases.. J Neurosci. (2001). 21 6933–9 [PubMed]
Khasar, SG, Lin, YH, Martin, A, Dadgar, J, McMahon, T, Wang, D, Hundle, B, Aley, KO, Isenberg, W, McCarter, G, Green, PG, Hodge, CW, Levine, JD, Messing, RO A novel nociceptor signaling pathway revealed in protein kinase C epsilon mutant mice.. Neuron. (1999). 24 253–60 [Article] [PubMed]
Khasar, SG, McCarter, G, Levine, JD Epinephrine produces a beta-adrenergic receptor-mediated mechanical hyperalgesia and in vitro sensitization of rat nociceptors.. J Neurophysiol. (1999). 81 1104–12 [PubMed]
Zhang, C, Rui, YY, Zhou, YY, Ju, Z, Zhang, HH, Hu, CY, Xiao, Y, Xu, GY Adrenergic β2-receptors mediates visceral hypersensitivity induced by heterotypic intermittent stress in rats.. PLoS One. (2014). 9 e94726 [Article] [PubMed]
Khasar, SG, Green, PG, Miao, FJ, Levine, JD Vagal modulation of nociception is mediated by adrenomedullary epinephrine in the rat.. Eur J Neurosci. (2003). 17 909–15 [Article] [PubMed]
Hucho, TB, Dina, OA, Kuhn, J, Levine, JD Estrogen controls PKCepsilon-dependent mechanical hyperalgesia through direct action on nociceptive neurons.. Eur J Neurosci. (2006). 24 527–34 [Article] [PubMed]
Ochoa-Cortes, F, Guerrero-Alba, R, Valdez-Morales, EE, Spreadbury, I, Barajas-Lopez, C, Castro, M, Bertrand, J, Cenac, N, Vergnolle, N, Vanner, SJ Chronic stress mediators act synergistically on colonic nociceptive mouse dorsal root ganglia neurons to increase excitability.. Neurogastroenterol Motil. (2014). 26 334–45 [Article] [PubMed]
Wang, S, Zhu, HY, Jin, Y, Zhou, Y, Hu, S, Liu, T, Jiang, X, Xu, GY Adrenergic signaling mediates mechanical hyperalgesia through activation of P2X3 receptors in primary sensory neurons of rats with chronic pancreatitis.. Am J Physiol Gastrointest Liver Physiol. (2015). 308 G710–9 [Article] [PubMed]
Dasu, MR, Ramirez, SR, La, TD, Gorouhi, F, Nguyen, C, Lin, BR, Mashburn, C, Stewart, H, Peavy, TR, Nolta, JA, Isseroff, RR Crosstalk between adrenergic and toll-like receptors in human mesenchymal stem cells and keratinocytes: A recipe for impaired wound healing.. Stem Cells Transl Med. (2014). 3 745–59 [Article] [PubMed]
Koizumi, H, Tanaka, H, Ohkawara, A beta-Adrenergic stimulation induces activation of protein kinase C and inositol 1,4,5-trisphosphate increase in epidermis.. Exp Dermatol. (1997). 6 128–32 [Article] [PubMed]
Pullar, CE, Isseroff, RR The beta 2-adrenergic receptor activates pro-migratory and pro-proliferative pathways in dermal fibroblasts via divergent mechanisms.. J Cell Sci. (2006). 119Pt 3 592–602 [Article] [PubMed]
Chi, DS, Fitzgerald, SM, Pitts, S, Cantor, K, King, E, Lee, SA, Huang, SK, Krishnaswamy, G MAPK-dependent regulation of IL-1- and beta-adrenoreceptor-induced inflammatory cytokine production from mast cells: Implications for the stress response.. BMC Immunol. (2004). 5 22 [Article] [PubMed]
Chiarella, SE, Soberanes, S, Urich, D, Morales-Nebreda, L, Nigdelioglu, R, Green, D, Young, JB, Gonzalez, A, Rosario, C, Misharin, AV, Ghio, AJ, Wunderink, RG, Donnelly, HK, Radigan, KA, Perlman, H, Chandel, NS, Budinger, GR, Mutlu, GM β2-Adrenergic agonists augment air pollution-induced IL-6 release and thrombosis.. J Clin Invest. (2014). 124 2935–46 [Article] [PubMed]
Kim, MH, Gorouhi, F, Ramirez, S, Granick, JL, Byrne, BA, Soulika, AM, Simon, SI, Isseroff, RR Catecholamine stress alters neutrophil trafficking and impairs wound healing by β2-adrenergic receptor-mediated upregulation of IL-6.. J Invest Dermatol. (2014). 134 809–17 [Article] [PubMed]
Laukova, M, Vargovic, P, Csaderova, L, Chovanova, L, Vlcek, M, Imrich, R, Krizanova, O, Kvetnansky, R Acute stress differently modulates β1, β2 and β3 adrenoceptors in T cells, but not in B cells, from the rat spleen.. Neuroimmunomodulation. (2012). 19 69–78 [Article] [PubMed]
Collins, S, Surwit, RS The beta-adrenergic receptors and the control of adipose tissue metabolism and thermogenesis.. Recent Prog Horm Res. (2001). 56 309–28 [Article] [PubMed]
Rainbow, TC, Parsons, B, Wolfe, BB Quantitative autoradiography of beta 1- and beta 2-adrenergic receptors in rat brain.. Proc Natl Acad Sci U S A. (1984). 81 1585–9 [Article] [PubMed]
Nicholson, R, Dixon, AK, Spanswick, D, Lee, K Noradrenergic receptor mRNA expression in adult rat superficial dorsal horn and dorsal root ganglion neurons.. Neurosci Lett. (2005). 380 316–21 [Article] [PubMed]
Stone, EA, Ariano, MA Are glial cells targets of the central noradrenergic system? A review of the evidence.. Brain Res Brain Res Rev. (1989). 14 297–309 [Article] [PubMed]
Kanno, T, Yaguchi, T, Nishizaki, T Noradrenaline stimulates ATP release from DRG neurons by targeting beta(3) adrenoceptors as a factor of neuropathic pain.. J Cell Physiol. (2010). 224 345–51 [Article] [PubMed]
Claustre, Y, Leonetti, M, Santucci, V, Bougault, I, Desvignes, C, Rouquier, L, Aubin, N, Keane, P, Busch, S, Chen, Y, Palejwala, V, Tocci, M, Yamdagni, P, Didier, M, Avenet, P, Le Fur, G, Oury-Donat, F, Scatton, B, Steinberg, R Effects of the beta3-adrenoceptor (Adrb3) agonist SR58611A (amibegron) on serotonergic and noradrenergic transmission in the rodent: Relevance to its antidepressant/anxiolytic-like profile.. Neuroscience. (2008). 156 353–64 [Article] [PubMed]
Berge, OG Predictive validity of behavioural animal models for chronic pain.. Br J Pharmacol. (2011). 164 1195–206 [Article] [PubMed]
Ren, K, Dubner, R Inflammatory models of pain and hyperalgesia.. ILAR J. (1999). 40 111–8 [Article] [PubMed]
Kim, KJ, Yoon, YW, Chung, JM Comparison of three rodent neuropathic pain models.. Exp Brain Res. (1997). 113 200–6 [Article] [PubMed]
Martin, LJ, Hathaway, G, Isbester, K, Mirali, S, Acland, EL, Niederstrasser, N, Slepian, PM, Trost, Z, Bartz, JA, Sapolsky, RM, Sternberg, WF, Levitin, DJ, Mogil, JS Reducing social stress elicits emotional contagion of pain in mouse and human strangers.. Curr Biol. (2015). 25 326–32 [Article] [PubMed]
Lariviere, WR, Mogil, JS The genetics of pain and analgesia in laboratory animals.. Methods Mol Biol. (2010). 617 261–78 [PubMed]
Haddad, F, Adams, GR Inhibition of MAP/ERK kinase prevents IGF-I-induced hypertrophy in rat muscles.. J Appl Physiol (1985). (2004). 96 203–10 [Article] [PubMed]
Yaksh, TL, Rudy, TA Chronic catheterization of the spinal subarachnoid space.. Physiol Behav. (1976). 17 1031–6 [Article] [PubMed]
DeVos, SL, Miller, TM Direct intraventricular delivery of drugs to the rodent central nervous system.. J Vis Exp. (2013).  e50326
Chaplan, SR, Bach, FW, Pogrel, JW, Chung, JM, Yaksh, TL Quantitative assessment of tactile allodynia in the rat paw.. J Neurosci Methods. (1994). 53 55–63 [Article] [PubMed]
Hargreaves, K, Dubner, R, Brown, F, Flores, C, Joris, J A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia.. Pain. (1988). 32 77–88 [Article] [PubMed]
Dumka, VK, Tandan, SK, Raviprakash, V, Tripathi, HC Central noradrenergic and cholinergic modulation of formaldehyde-induced pedal inflammation and nociception in rats.. Indian J Physiol Pharmacol. (1996). 40 41–6 [PubMed]
Fukui, M, Nakagawa, T, Minami, M, Satoh, M Involvement of beta2-adrenergic and mu-opioid receptors in antinociception produced by intracerebroventricular administration of alpha,beta-methylene-ATP.. Jpn J Pharmacol. (2001). 86 423–8 [Article] [PubMed]
Kanzler, SA, Januario, AC, Paschoalini, MA Involvement of β3-adrenergic receptors in the control of food intake in rats.. Braz J Med Biol Res. (2011). 44 1141–7 [Article] [PubMed]
Kubota, E, Kubota, T, Matsumoto, J, Shibata, T, Murakami, KI Synovial fluid cytokines and proteinases as markers of temporomandibular joint disease.. J Oral Maxillofac Surg. (1998). 56 192–8 [Article] [PubMed]
Uzar, E, Evliyaoglu, O, Yucel, Y, Ugur Cevik, M, Acar, A, Guzel, I, Islamoglu, Y, Colpan, L, Tasdemir, N Serum cytokine and pro-brain natriuretic peptide (BNP) levels in patients with migraine.. Eur Rev Med Pharmacol Sci. (2011). 15 1111–6 [PubMed]
Sarchielli, P, Alberti, A, Baldi, A, Coppola, F, Rossi, C, Pierguidi, L, Floridi, A, Calabresi, P Proinflammatory cytokines, adhesion molecules, and lymphocyte integrin expression in the internal jugular blood of migraine patients without aura assessed ictally.. Headache. (2006). 46 200–7 [Article] [PubMed]
Slade, GD, Conrad, MS, Diatchenko, L, Rashid, NU, Zhong, S, Smith, S, Rhodes, J, Medvedev, A, Makarov, S, Maixner, W, Nackley, AG Cytokine biomarkers and chronic pain: Association of genes, transcription, and circulating proteins with temporomandibular disorders and widespread palpation tenderness.. Pain. (2011). 152 2802–12 [Article] [PubMed]
Omote, K, Hazama, K, Kawamata, T, Kawamata, M, Nakayaka, Y, Toriyabe, M, Namiki, A Peripheral nitric oxide in carrageenan-induced inflammation.. Brain Res. (2001). 912 171–5 [Article] [PubMed]
Holguin, A, O’Connor, KA, Biedenkapp, J, Campisi, J, Wieseler-Frank, J, Milligan, ED, Hansen, MK, Spataro, L, Maksimova, E, Bravmann, C, Martin, D, Fleshner, M, Maier, SF, Watkins, LR HIV-1 gp120 stimulates proinflammatory cytokine-mediated pain facilitation via activation of nitric oxide synthase-I (nNOS).. Pain. (2004). 110 517–30 [Article] [PubMed]
Kuboyama, K, Tsuda, M, Tsutsui, M, Toyohara, Y, Tozaki-Saitoh, H, Shimokawa, H, Yanagihara, N, Inoue, K Reduced spinal microglial activation and neuropathic pain after nerve injury in mice lacking all three nitric oxide synthases.. Mol Pain. (2011). 7 50 [Article] [PubMed]
Boehning, D, Snyder, SH Novel neural modulators.. Annu Rev Neurosci. (2003). 26 105–31 [Article] [PubMed]
Aley, KO, McCarter, G, Levine, JD Nitric oxide signaling in pain and nociceptor sensitization in the rat.. J Neurosci. (1998). 18 7008–14 [PubMed]
Czeschik, JC, Hagenacker, T, Schäfers, M, Büsselberg, D TNF-alpha differentially modulates ion channels of nociceptive neurons.. Neurosci Lett. (2008). 434 293–8 [Article] [PubMed]
Binshtok, AM, Wang, H, Zimmermann, K, Amaya, F, Vardeh, D, Shi, L, Brenner, GJ, Ji, RR, Bean, BP, Woolf, CJ, Samad, TA Nociceptors are interleukin-1beta sensors.. J Neurosci. (2008). 28 14062–73 [Article] [PubMed]
Obreja, O, Biasio, W, Andratsch, M, Lips, KS, Rathee, PK, Ludwig, A, Rose-John, S, Kress, M Fast modulation of heat-activated ionic current by proinflammatory interleukin 6 in rat sensory neurons.. Brain. (2005). 128Pt 7 1634–41 [Article] [PubMed]
Obreja, O, Rathee, PK, Lips, KS, Distler, C, Kress, M IL-1 beta potentiates heat-activated currents in rat sensory neurons: Involvement of IL-1RI, tyrosine kinase, and protein kinase C.. FASEB J. (2002). 16 1497–503 [Article] [PubMed]
Jung, H, Toth, PT, White, FA, Miller, RJ Monocyte chemoattractant protein-1 functions as a neuromodulator in dorsal root ganglia neurons.. J Neurochem. (2008). 104 254–63 [PubMed]
Sun, JH, Yang, B, Donnelly, DF, Ma, C, LaMotte, RH MCP-1 enhances excitability of nociceptive neurons in chronically compressed dorsal root ganglia.. J Neurophysiol. (2006). 96 2189–99 [Article] [PubMed]
Vissers, KC, De Jongh, RF, Crul, BJ, Vinken, P, Meert, TF Adrenalectomy affects pain behavior of rats after formalin injection.. Life Sci. (2004). 74 1243–51 [Article] [PubMed]
Wang, S, Lim, G, Zeng, Q, Sung, B, Ai, Y, Guo, G, Yang, L, Mao, J Expression of central glucocorticoid receptors after peripheral nerve injury contributes to neuropathic pain behaviors in rats.. J Neurosci. (2004). 24 8595–605 [Article] [PubMed]
Marinelli, M, Piazza, PV, Deroche, V, Maccari, S, Le Moal, M, Simon, H Corticosterone circadian secretion differentially facilitates dopamine-mediated psychomotor effect of cocaine and morphine.. J Neurosci. (1994). 145 Pt 1 2724–31 [PubMed]
Taylor, BK, Akana, SF, Peterson, MA, Dallman, MF, Basbaum, AI Pituitary-adrenocortical responses to persistent noxious stimuli in the awake rat: Endogenous corticosterone does not reduce nociception in the formalin test.. Endocrinology. (1998). 139 2407–13 [PubMed]
Sorge, RE, Martin, LJ, Isbester, KA, Sotocinal, SG, Rosen, S, Tuttle, AH, Wieskopf, JS, Acland, EL, Dokova, A, Kadoura, B, Leger, P, Mapplebeck, JC, McPhail, M, Delaney, A, Wigerblad, G, Schumann, AP, Quinn, T, Frasnelli, J, Svensson, CI, Sternberg, WF, Mogil, JS Olfactory exposure to males, including men, causes stress and related analgesia in rodents.. Nat Methods. (2014). 11 629–32 [Article] [PubMed]
Wang, S, Lim, G, Zeng, Q, Sung, B, Yang, L, Mao, J Central glucocorticoid receptors modulate the expression and function of spinal NMDA receptors after peripheral nerve injury.. J Neurosci. (2005). 25 488–95 [Article] [PubMed]
Wang, S, Lim, G, Yang, L, Sung, B, Mao, J Downregulation of spinal glutamate transporter EAAC1 following nerve injury is regulated by central glucocorticoid receptors in rats.. Pain. (2006). 120 78–85 [Article] [PubMed]
Gogos, JA, Morgan, M, Luine, V, Santha, M, Ogawa, S, Pfaff, D, Karayiorgou, M Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior.. Proc Natl Acad Sci U S A. (1998). 95 9991–6 [Article] [PubMed]
Papaleo, F, Crawley, JN, Song, J, Lipska, BK, Pickel, J, Weinberger, DR, Chen, J Genetic dissection of the role of catechol-O-methyltransferase in cognition and stress reactivity in mice.. J Neurosci. (2008). 28 8709–23 [Article] [PubMed]
Harrison, PJ, Tunbridge, EM Catechol-O-methyltransferase (COMT): a gene contributing to sex differences in brain function, and to sexual dimorphism in the predisposition to psychiatric disorders.. Neuropsychopharmacology. (2008). 33 3037–45 [Article] [PubMed]
White, TP, Loth, E, Rubia, K, Krabbendam, L, Whelan, R, Banaschewski, T, Barker, GJ, Bokde, AL, Büchel, C, Conrod, P, Fauth-Bühler, M, Flor, H, Frouin, V, Gallinat, J, Garavan, H, Gowland, P, Heinz, A, Ittermann, B, Lawrence, C, Mann, K, Paillère, ML, Nees, F, Paus, T, Pausova, Z, Rietschel, M, Robbins, T, Smolka, MN, Shergill, SS, Schumann, G IMAGEN Consortium, IMAGEN Consortium, Sex differences in COMT polymorphism effects on prefrontal inhibitory control in adolescence.. Neuropsychopharmacology. (2014). 39 2560–9 [Article] [PubMed]
Belfer, I, Segall, SK, Lariviere, WR, Smith, SB, Dai, F, Slade, GD, Rashid, NU, Mogil, JS, Campbell, CM, Edwards, RR, Liu, Q, Bair, E, Maixner, W, Diatchenko, L Pain modality- and sex-specific effects of COMT genetic functional variants.. Pain. (2013). 154 1368–76 [Article] [PubMed]
Boudíková, B, Szumlanski, C, Maidak, B, Weinshilboum, R Human liver catechol-O-methyltransferase pharmacogenetics.. Clin Pharmacol Ther. (1990). 48 381–9 [Article] [PubMed]
Chen, LX, Fang, Q, Chen, Q, Guo, J, Wang, ZZ, Chen, Y, Wang, R Study in vitro and in vivo of nociceptin/orphanin FQ(1-13)NH2 analogues substituting N-Me-Gly for Gly2 or Gly3.. Peptides. (2004). 25 1349–54 [Article] [PubMed]
Diatchenko, L, Anderson, AD, Slade, GD, Fillingim, RB, Shabalina, SA, Higgins, TJ, Sama, S, Belfer, I, Goldman, D, Max, MB, Weir, BS, Maixner, W Three major haplotypes of the beta2 adrenergic receptor define psychological profile, blood pressure, and the risk for development of a common musculoskeletal pain disorder.. Am J Med Genet B Neuropsychiatr Genet. (2006). 141B 449–62 [Article] [PubMed]
Strosberg, AD Structure and function of the beta 3-adrenergic receptor.. Annu Rev Pharmacol Toxicol. (1997). 37 421–50 [Article] [PubMed]
Fávaro-Moreira, NC, Parada, CA, Tambeli, CH Blockade of β1-, β2- and β3-adrenoceptors in the temporomandibular joint induces antinociception especially in female rats.. Eur J Pain. (2012). 16 1302–10 [Article] [PubMed]
Liggett, SB, Freedman, NJ, Schwinn, DA, Lefkowitz, RJ Structural basis for receptor subtype-specific regulation revealed by a chimeric beta 3/beta 2-adrenergic receptor.. Proc Natl Acad Sci U S A. (1993). 90 3665–9 [Article] [PubMed]
Cao, W, Luttrell, LM, Medvedev, AV, Pierce, KL, Daniel, KW, Dixon, TM, Lefkowitz, RJ, Collins, S Direct binding of activated c-Src to the beta 3-adrenergic receptor is required for MAP kinase activation.. J Biol Chem. (2000). 275 38131–4 [Article] [PubMed]
Slota, C, Shi, A, Chen, G, Bevans, M, Weng, NP Norepinephrine preferentially modulates memory CD8 T cell function inducing inflammatory cytokine production and reducing proliferation in response to activation.. Brain Behav Immun. (2015). 46 168–79 [Article] [PubMed]
Costigan, M, Moss, A, Latremoliere, A, Johnston, C, Verma-Gandhu, M, Herbert, TA, Barrett, L, Brenner, GJ, Vardeh, D, Woolf, CJ, Fitzgerald, M T-cell infiltration and signaling in the adult dorsal spinal cord is a major contributor to neuropathic pain-like hypersensitivity.. J Neurosci. (2009). 29 14415–22 [Article] [PubMed]
Vicuña, L, Strochlic, DE, Latremoliere, A, Bali, KK, Simonetti, M, Husainie, D, Prokosch, S, Riva, P, Griffin, RS, Njoo, C, Gehrig, S, Mall, MA, Arnold, B, Devor, M, Woolf, CJ, Liberles, SD, Costigan, M, Kuner, R The serine protease inhibitor SerpinA3N attenuates neuropathic pain by inhibiting T cell-derived leukocyte elastase.. Nat Med. (2015). 21 518–23 [Article] [PubMed]
Russell, IJ, Vipraio, GA, Michalek, JE, Craig, FE, Kang, YK, Richards, AB Lymphocyte markers and natural killer cell activity in fibromyalgia syndrome: Effects of low-dose, sublingual use of human interferon-alpha.. J Interferon Cytokine Res. (1999). 19 969–78 [Article] [PubMed]
Feng, B, La, JH, Schwartz, ES, Gebhart, GF Irritable bowel syndrome: Methods, mechanisms, and pathophysiology. Neural and neuro-immune mechanisms of visceral hypersensitivity in irritable bowel syndrome.. Am J Physiol Gastrointest Liver Physiol. (2012). 302 G1085–98 [Article] [PubMed]
Graziottin, A, Skaper, SD, Fusco, M Mast cells in chronic inflammation, pelvic pain and depression in women.. Gynecol Endocrinol. (2014). 30 472–7 [Article] [PubMed]
Levy, D Migraine pain, meningeal inflammation, and mast cells.. Curr Pain Headache Rep. (2009). 13 237–40 [Article] [PubMed]
Petra, AI, Panagiotidou, S, Stewart, JM, Conti, P, Theoharides, TC Spectrum of mast cell activation disorders.. Expert Rev Clin Immunol. (2014). 10 729–39 [Article] [PubMed]
Regauer, S, Eberz, B, Beham-Schmid, C Mast cell infiltrates in vulvodynia represent secondary and idiopathic mast cell hyperplasias.. APMIS. (2015). 123 452–6 [Article] [PubMed]
Zhang, Z, Cherryholmes, G, Mao, A, Marek, C, Longmate, J, Kalos, M, Amand, RP, Shively, JE High plasma levels of MCP-1 and eotaxin provide evidence for an immunological basis of fibromyalgia.. Exp Biol Med (Maywood). (2008). 233 1171–80 [Article] [PubMed]
Vieira-Potter, VJ Inflammation and macrophage modulation in adipose tissues.. Cell Microbiol. (2014). 16 1484–92 [Article] [PubMed]
Mohamed-Ali, V, Goodrick, S, Rawesh, A, Katz, DR, Miles, JM, Yudkin, JS, Klein, S, Coppack, SW Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo.. J Clin Endocrinol Metab. (1997). 82 4196–200 [PubMed]
Mohamed-Ali, V, Flower, L, Sethi, J, Hotamisligil, G, Gray, R, Humphries, SE, York, DA, Pinkney, J beta-Adrenergic regulation of IL-6 release from adipose tissue: In vivo and in vitro studies.. J Clin Endocrinol Metab. (2001). 86 5864–9 [PubMed]
Fu, L, Isobe, K, Zeng, Q, Suzukawa, K, Takekoshi, K, Kawakami, Y beta-adrenoceptor agonists downregulate adiponectin, but upregulate adiponectin receptor 2 and tumor necrosis factor-alpha expression in adipocytes.. Eur J Pharmacol. (2007). 569 155–62 [Article] [PubMed]
Kralisch, S, Klein, J, Lossner, U, Bluher, M, Paschke, R, Stumvoll, M, Fasshauer, M Isoproterenol stimulates monocyte chemoattractant protein-1 expression and secretion in 3T3-L1 adipocytes.. Regul Pept. (2006). 135 12–6 [Article] [PubMed]
Canová, NK, Lincová, D, Kmonícková, E, Kameníková, L, Farghali, H Nitric oxide production from rat adipocytes is modulated by beta3-adrenergic receptor agonists and is involved in a cyclic AMP-dependent lipolysis in adipocytes.. Nitric Oxide. (2006). 14 200–11 [Article] [PubMed]
Gilman, AG, Nirenberg, M Effect of catecholamines on the adenosine 3’:5’-cyclic monophosphate concentrations of clonal satellite cells of neurons.. Proc Natl Acad Sci U S A. (1971). 68 2165–8 [Article] [PubMed]
Wood, PB, Kablinger, AS, Caldito, GS Open trial of pindolol in the treatment of fibromyalgia.. Ann Pharmacother. (2005). 39 1812–6 [Article] [PubMed]
Rodrigues, WF, Madeira, MF, da Silva, TA, Clemente-Napimoga, JT, Miguel, CB, Dias-da-Silva, VJ, Barbosa-Neto, O, Lopes, AH, Napimoga, MH Low dose of propranolol down-modulates bone resorption by inhibiting inflammation and osteoclast differentiation.. Br J Pharmacol. (2012). 165 2140–51 [Article] [PubMed]
Park, JM, Mun, JH, Song, M, Kim, HS, Kim, BS, Kim, MB, Ko, HC Propranolol, doxycycline and combination therapy for the treatment of rosacea.. J Dermatol. (2015). 42 64–9 [Article] [PubMed]
Kaplan, R, Robinson, CA, Scavulli, JF, Vaughan, JH Propranolol and the treatment of rheumatoid arthritis.. Arthritis Rheum. (1980). 23 253–5 [Article] [PubMed]
Hogan, CJ, Hurwitz, SR Treatment of complex regional pain syndrome of the lower extremity.. J Am Acad Orthop Surg. (2002). 10 281–9 [Article] [PubMed]
Millan, MJ Descending control of pain.. Prog Neurobiol. (2002). 66 355–474 [Article] [PubMed]
Sánchez, C, Hyttel, J Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding.. Cell Mol Neurobiol. (1999). 19 467–89 [Article] [PubMed]
Li, W, Shi, X, Wang, L, Guo, T, Wei, T, Cheng, K, Rice, KC, Kingery, WS, Clark, JD Epidermal adrenergic signaling contributes to inflammation and pain sensitization in a rat model of complex regional pain syndrome.. Pain. (2013). 154 1224–36 [Article] [PubMed]
Fig. 1.
Sustained administration of the catecholamine-O-methyltransferase inhibitor OR486 leads to mechanical and thermal hypersensitivity. Compared to vehicle, sustained systemic OR486 administration produces (A) mechanical allodynia, (B) mechanical hyperalgesia, and (C) thermal hyperalgesia. N = 12 (6 males and 6 females) per group. Data are expressed as mean ± SEM. ***P < 0.001, **P < 0.01 different from vehicle. BL = baseline; Veh = vehicle.
Sustained administration of the catecholamine-O-methyltransferase inhibitor OR486 leads to mechanical and thermal hypersensitivity. Compared to vehicle, sustained systemic OR486 administration produces (A) mechanical allodynia, (B) mechanical hyperalgesia, and (C) thermal hyperalgesia. N = 12 (6 males and 6 females) per group. Data are expressed as mean ± SEM. ***P < 0.001, **P < 0.01 different from vehicle. BL = baseline; Veh = vehicle.
Fig. 1.
Sustained administration of the catecholamine-O-methyltransferase inhibitor OR486 leads to mechanical and thermal hypersensitivity. Compared to vehicle, sustained systemic OR486 administration produces (A) mechanical allodynia, (B) mechanical hyperalgesia, and (C) thermal hyperalgesia. N = 12 (6 males and 6 females) per group. Data are expressed as mean ± SEM. ***P < 0.001, **P < 0.01 different from vehicle. BL = baseline; Veh = vehicle.
×
Fig. 2.
Adrenalectomized (Adx) rats fail to develop OR486-induced hypersensitivity. In Sham (Shm), but not Adx, animals, sustained systemic OR486 administration produces (A) mechanical allodynia, (B) mechanical hyperalgesia, and (C) thermal hyperalgesia. N = 11 (5 males and 6 females) for Shm/vehicle (Veh) and N = 12 (6 males and 6 females) for all other groups. Data are expressed as mean ± SEM. ***P < 0.001, **P < 0.01, *P < 0.05 different from Shm/Veh. BL = Baseline.
Adrenalectomized (Adx) rats fail to develop OR486-induced hypersensitivity. In Sham (Shm), but not Adx, animals, sustained systemic OR486 administration produces (A) mechanical allodynia, (B) mechanical hyperalgesia, and (C) thermal hyperalgesia. N = 11 (5 males and 6 females) for Shm/vehicle (Veh) and N = 12 (6 males and 6 females) for all other groups. Data are expressed as mean ± SEM. ***P < 0.001, **P < 0.01, *P < 0.05 different from Shm/Veh. BL = Baseline.
Fig. 2.
Adrenalectomized (Adx) rats fail to develop OR486-induced hypersensitivity. In Sham (Shm), but not Adx, animals, sustained systemic OR486 administration produces (A) mechanical allodynia, (B) mechanical hyperalgesia, and (C) thermal hyperalgesia. N = 11 (5 males and 6 females) for Shm/vehicle (Veh) and N = 12 (6 males and 6 females) for all other groups. Data are expressed as mean ± SEM. ***P < 0.001, **P < 0.01, *P < 0.05 different from Shm/Veh. BL = Baseline.
×
Fig. 3.
Peripheral administration of β-adrenergic receptor (βAR) antagonists blocks OR486-induced hypersensitivity. Peripheral delivery of the nonselective βAR antagonist propranolol (Prop) alongside sustained systemic OR486 administration prevents (A) mechanical allodynia and (D) mechanical hyperalgesia but does not alter (G) thermal hyperalgesia. Similarly, peripheral delivery of the β2AR antagonist ICI-118,551 (ICI) alongside sustained systemic OR486 administration prevents (B) mechanical allodynia and (E) mechanical hyperalgesia but does not alter (H) thermal hyperalgesia. Finally, peripheral delivery of the β3AR antagonist SR59230A (SR) alongside sustained systemic OR486 administration prevents (C) mechanical allodynia, (F) mechanical hyperalgesia, and (I) thermal hyperalgesia. N = 9 per group. Data are expressed as mean ± SEM. ***P < 0.001, **P < 0.01, *P < 0.05 different from vehicle (Veh)/Veh. BL = Baseline.
Peripheral administration of β-adrenergic receptor (βAR) antagonists blocks OR486-induced hypersensitivity. Peripheral delivery of the nonselective βAR antagonist propranolol (Prop) alongside sustained systemic OR486 administration prevents (A) mechanical allodynia and (D) mechanical hyperalgesia but does not alter (G) thermal hyperalgesia. Similarly, peripheral delivery of the β2AR antagonist ICI-118,551 (ICI) alongside sustained systemic OR486 administration prevents (B) mechanical allodynia and (E) mechanical hyperalgesia but does not alter (H) thermal hyperalgesia. Finally, peripheral delivery of the β3AR antagonist SR59230A (SR) alongside sustained systemic OR486 administration prevents (C) mechanical allodynia, (F) mechanical hyperalgesia, and (I) thermal hyperalgesia. N = 9 per group. Data are expressed as mean ± SEM. ***P < 0.001, **P < 0.01, *P < 0.05 different from vehicle (Veh)/Veh. BL = Baseline.
Fig. 3.
Peripheral administration of β-adrenergic receptor (βAR) antagonists blocks OR486-induced hypersensitivity. Peripheral delivery of the nonselective βAR antagonist propranolol (Prop) alongside sustained systemic OR486 administration prevents (A) mechanical allodynia and (D) mechanical hyperalgesia but does not alter (G) thermal hyperalgesia. Similarly, peripheral delivery of the β2AR antagonist ICI-118,551 (ICI) alongside sustained systemic OR486 administration prevents (B) mechanical allodynia and (E) mechanical hyperalgesia but does not alter (H) thermal hyperalgesia. Finally, peripheral delivery of the β3AR antagonist SR59230A (SR) alongside sustained systemic OR486 administration prevents (C) mechanical allodynia, (F) mechanical hyperalgesia, and (I) thermal hyperalgesia. N = 9 per group. Data are expressed as mean ± SEM. ***P < 0.001, **P < 0.01, *P < 0.05 different from vehicle (Veh)/Veh. BL = Baseline.
×
Fig. 4.
Intrathecal administration of β-adrenergic receptor (βAR) antagonists does not alter OR486-induced hypersensitivity. Intrathecal delivery of the nonselective βAR antagonist propranolol (prop) (A, D, G), the β2AR antagonist ICI-118,551 (ICI) (B, E, H), or the β3AR antagonist SR59230A (SR) (C, F, I) alongside sustained systemic OR486 administration does not alter mechanical or thermal sensitivity. N = 4 per group. Data are expressed as mean ± SEM. ***P < 0.001, **P < 0.01, *P < 0.05 different from vehicle (Veh)/Veh. BL = Baseline.
Intrathecal administration of β-adrenergic receptor (βAR) antagonists does not alter OR486-induced hypersensitivity. Intrathecal delivery of the nonselective βAR antagonist propranolol (prop) (A, D, G), the β2AR antagonist ICI-118,551 (ICI) (B, E, H), or the β3AR antagonist SR59230A (SR) (C, F, I) alongside sustained systemic OR486 administration does not alter mechanical or thermal sensitivity. N = 4 per group. Data are expressed as mean ± SEM. ***P < 0.001, **P < 0.01, *P < 0.05 different from vehicle (Veh)/Veh. BL = Baseline.
Fig. 4.
Intrathecal administration of β-adrenergic receptor (βAR) antagonists does not alter OR486-induced hypersensitivity. Intrathecal delivery of the nonselective βAR antagonist propranolol (prop) (A, D, G), the β2AR antagonist ICI-118,551 (ICI) (B, E, H), or the β3AR antagonist SR59230A (SR) (C, F, I) alongside sustained systemic OR486 administration does not alter mechanical or thermal sensitivity. N = 4 per group. Data are expressed as mean ± SEM. ***P < 0.001, **P < 0.01, *P < 0.05 different from vehicle (Veh)/Veh. BL = Baseline.
×
Fig. 5.
Intracerebroventricular administration of β-adrenergic receptor (βAR) antagonists does not alter OR486-induced hypersensitivity. Supraspinal delivery of the nonselective βAR antagonist propranolol (prop) (A, D, G), β2AR antagonist ICI-118,551 (ICI) (B, E, H), or the β3AR antagonist SR59230A (SR) (C, F, I) alongside sustained systemic OR486 administration does not alter mechanical or thermal sensitivity. N = 4–5 per group. Data are expressed as mean ± SEM. ***P < 0.001, **P < 0.01, *P < 0.05 different from vehicle (Veh)/Veh. BL = Baseline.
Intracerebroventricular administration of β-adrenergic receptor (βAR) antagonists does not alter OR486-induced hypersensitivity. Supraspinal delivery of the nonselective βAR antagonist propranolol (prop) (A, D, G), β2AR antagonist ICI-118,551 (ICI) (B, E, H), or the β3AR antagonist SR59230A (SR) (C, F, I) alongside sustained systemic OR486 administration does not alter mechanical or thermal sensitivity. N = 4–5 per group. Data are expressed as mean ± SEM. ***P < 0.001, **P < 0.01, *P < 0.05 different from vehicle (Veh)/Veh. BL = Baseline.
Fig. 5.
Intracerebroventricular administration of β-adrenergic receptor (βAR) antagonists does not alter OR486-induced hypersensitivity. Supraspinal delivery of the nonselective βAR antagonist propranolol (prop) (A, D, G), β2AR antagonist ICI-118,551 (ICI) (B, E, H), or the β3AR antagonist SR59230A (SR) (C, F, I) alongside sustained systemic OR486 administration does not alter mechanical or thermal sensitivity. N = 4–5 per group. Data are expressed as mean ± SEM. ***P < 0.001, **P < 0.01, *P < 0.05 different from vehicle (Veh)/Veh. BL = Baseline.
×